Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

BACKGROUND: Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in the neoadjuvant setting, but their role as adjuvant therapy remains uncertain. METHODS: In the Adjuvant Lapatinib a...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: Piccart-Gebhart, Martine, Holmes, Eileen, Baselga, José, de Azambuja, Evandro, Dueck, Amylou C., Viale, Giuseppe, Zujewski, Jo Anne, Goldhirsch, Aron, Armour, Alison, Pritchard, Kathleen I., McCullough, Ann E., Dolci, Stella, McFadden, Eleanor, Holmes, Andrew P., Tonghua, Liu, Eidtmann, Holger, Dinh, Phuong, Di Cosimo, Serena, Harbeck, Nadia, Tjulandin, Sergei, Im, Young-Hyuck, Huang, Chiun-Sheng, Diéras, Véronique, Hillman, David W., Wolff, Antonio C., Jackisch, Christian, Lang, Istvan, Untch, Michael, Smith, Ian, Boyle, Frances, Xu, Binghe, Gomez, Henry, Suter, Thomas, Gelber, Richard D., Perez, Edith A.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2016
Subjects:
ORIGINAL REPORTS
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872016/
https://ncbi.nlm.nih.gov/pubmed/26598744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.1797
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items